Abstracts Archive - Page 2396 of 2607 - ACR Meeting Abstracts

Abstract Number: 529 • 2013 ACR/ARHP Annual Meeting
Ankylosing Spondylitis and Dysfunctional Dkk
Rajbir Gulati¹, Maripat Corr², Michael H. Weisman³ and David Hallegua⁴, ¹Rheumatology, Cedars Sinai Medical Center, Los Angeles, CA, ²Medicine, Univ of California-San Diego, La Jolla, CA, ³Rheumatology, Cedars-Sinai Medical Center, Los Angeles, CA, ⁴Medicine, Cedars-Sinai/UCLA, Beverly Hills, CA
Background/Purpose: Ankylosing Spondylitis (AS) is characterized by inflammation of the spine and entheses followed by formation of syndesmophytes. Wnt pathway is a regulator of bone…
Abstract Number: 530 • 2013 ACR/ARHP Annual Meeting
Pattern Recognition Receptor Stimulated Cytokine Expression By Spondyloarthritis Patient Macrophages
Yi-Ping Liu¹, Ashley Bomkamp², Jens Eickhoff³, Jack Schneck², Mike Khan⁴ and Judith Smith⁵, ¹Department of Pediatrics, University of Wisconsin-Madison, Madison, WI, ²University of Wisconsin-Madison, Madison, WI, ³Biostatistics and Medical Informatics, University of Wisconsin-Madison, Madison, WI, ⁴Cellular and Molecular Pathology, University of Wisconsin-Madison, Madison, WI, ⁵Pediatrics, University of Wisconsin-Madison, Madison, WI
Background/Purpose: Spondyloarthritis (SpA) encompasses a group of chronic inflammatory conditions involving axial arthritis that includes ankylosing spondylitis (AS). GWAS studies in AS have implicated multiple…
Abstract Number: 532 • 2013 ACR/ARHP Annual Meeting
Role Of Baseline C-Reactive Protein In Response To Infliximab Plus Naproxen Vs Naproxen Alone In Patients With Axial Spondyloarthritis
J Sieper¹, M Rudwaleit¹, J Lenaerts², J Wollenhaupt³, L Myasoutova⁴, S Park⁵, Y Song⁶, R Yao⁷, M Govoni⁸, D Chitkara⁹ and N Vastesaeger¹⁰, ¹University Clinic Benjamin Franklin, Berlin, Germany, ²Practice Rheumatology, Hasselt, Belgium, ³Schön-Klinik, Hamburg, Germany, ⁴Kazan State Medical University, Kazan, Russia, ⁵Catholic University of Korea, Seoul, South Korea, ⁶Seoul National University, Seoul, South Korea, ⁷Merck & Co., Inc., Whitehouse Station, NJ, ⁸MSD Italy, Rome, Italy, ⁹Merck Sharp & Dohme, Kenilworth, NJ, ¹⁰Merck Sharp & Dohme, Brussels, Belgium
Background/Purpose: Baseline inflammation has been shown to influence response to tumor necrosis factor alpha antagonist treatment in patients with axial spondyloarthritis (SpA). This study evaluated…
Abstract Number: 535 • 2013 ACR/ARHP Annual Meeting
Death Receptor 3 Increases Region-Specific, Osteoblast-Dependent Aberrant New Bone Formation In The Axial Skeleton Of Mice In a Spontaneous Model Of Ankylosing Enthesopathy
Fraser L. Collins¹, Jessica O Williams², Anja C. Bloom¹, Michael D. Stone³, Ernest Choy¹, Edward C. Wang⁴ and Anwen S. Williams⁵, ¹Section of Rheumatology, Cardiff University, Institute of Infection and Immunity, Cardiff, United Kingdom, ²Institute of Molecular and Experimental Medicine, Cardiff University School of Medicine, Cardiff, United Kingdom, ³University Hospital Llandough, Cardiff & Vale University Health Board, Cardiff, United Kingdom, ⁴Cardiff University, Institute of Infection and Immunity, Cardiff, United Kingdom, ⁵Institute of Infection and Immunity, Cardiff University School of Medicine, Cardiff, United Kingdom
Background/Purpose: Clinical management of localised bone formation and joint ankylosis constitute major challenges in patients with seronegative inflammatory spondyloarthropathies (SpAs). Whether TNF receptor superfamily members,…
Abstract Number: 536 • 2013 ACR/ARHP Annual Meeting
Membrane-Bound TNF Drives Axial and Peripheral Inflammation and Pathologic New Bone Formation
Leonie M. van Duivenvoorde¹, Melissa N. van Tok¹ and Dominique L. Baeten², ¹Clinical Immunology and Rheumatology, Academic Medical Center / University of Amsterdam, Amsterdam, Netherlands, ²Clinical Immunology and Rheumatology, Academic Medical Center/University of Amsterdam, Amsterdam, Netherlands
Background/Purpose: The morbidity of spondyloarthritis (SpA) is determined not only by inflammation but also by structural damage, in particular osteoproliferation leading to joint ankylosis. The…
Abstract Number: 537 • 2013 ACR/ARHP Annual Meeting
Investigating a Novel Locus For Psoriatic Arthritis
Ashley Budu-Aggrey^1,2, John Bowes¹, Pauline Ho^1,3, James Bluett¹, Harry Hébert^1,4, Helena Marzo-Ortega⁵, Ann W. Morgan⁶, Matthew A. Brown⁷, Ross McManus⁸, Neil McHugh⁹, Oliver FitzGerald¹⁰, Ian N. Bruce^2,11,12 and Anne Barton^1,2, ¹Arthritis Research UK Epidemiology Unit, Centre for Musculoskeletal Research, Institute of Inflammation and repair, Manchester Academic Health Science Centre, The University of Manchester, Manchester, United Kingdom, ²NIHR Manchester Musculoskeletal Biomedical Research Unit, Manchester Academy of Health Sciences, Manchester, United Kingdom, ³NIHR Manchester Musculoskeletal Biomedical Research Unit, Manchester Academic Health Science Centre, Manchester, United Kingdom, ⁴The Dermatology Centre, Salford Royal NHS Foundation Trust, University of Manchester, Manchester Academic Health Science Centre, Manchester, United Kingdom, ⁵LMBRU, Chapel Allerton Hospital, and University of Leeds, Leeds, United Kingdom, ⁶NIHR-Leeds Musculoskeletal Biomedical Research Unit and Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, United Kingdom, ⁷Human Genetics Group, The University of Queensland Diamantina Insititute, Brisbane, Australia, ⁸Department of Clinical Medicine, Institute of Molecular Medicine, Trinity College Dublin, Ireland, Dublin, Ireland, ⁹Department of Rheumatology, Royal National Hospital for Rheumatic Diseases, Bath, United Kingdom, ¹⁰Department of Rheumatology, St.Vincent's University Hospital, Dublin, Ireland, ¹¹Arthritis Research UK Centre for Epidemiology, Centre for Musculoskeletal Research, Institute of Inflammation and repair, Manchester Academic Health Science Centre, The University of Manchester, Manchester, United Kingdom, ¹²Kellgren Centre for Rheumatology, Central Manchester University Hospitals Trust, Manchester Academic Health Science Centre, Manchester, United Kingdom
Background/Purpose: Psoriatic arthritis (PsA) is a complex genetic disorder with a prevalence of up to 1% in the general population. The association of PsA with…
Abstract Number: 538 • 2013 ACR/ARHP Annual Meeting
Ankylosing Spondylitis Associated Endoplasmic Reticulum Aminopeptidase 1 Variants Alter The Unfolded Protein Response
Nigil Haroon^1,2,3 and Zhenbo Zhang³, ¹Rheumatology, University Health Network, Toronto, ON, Canada, ²Medicine, Rheumatology, University of Toronto, Toronto, ON, Canada, ³Toronto Western Research Institute, Toronto, ON, Canada
Background/Purpose: Endoplasmic reticulum aminopeptidase 1 (ERAP1) has recently been identified to be strongly associated with HLA-B27 positive AS. We have shown that ERAP1 variants cause…
Abstract Number: 540 • 2013 ACR/ARHP Annual Meeting
Exploration Of a Novel Therapeutic Target In a Murine Model Of Systemic Lupus Erythematosus: Targeting Sphingosine-1-Phosphate (S1P) Receptors
Christopher Tracy¹, Jess Edison², S. Frattalone² and C. Moratz³, ¹Internal Medicine-Rheumatology, Walter Reed National Military Medical Center, Bethesda, MD, ²Department of Rheumatology, Walter Reed National Military Medical Center, Bethesda, MD, ³Department of Medicine, Uniformed Services University of Health Sciences, Bethesda, MD
Background/Purpose: Systemic lupus erythematous (SLE) is an autoimmune disease characterized by symptomatic flares that often result in terminal organ failure. The pathogenesis is characterized by…
Abstract Number: 541 • 2013 ACR/ARHP Annual Meeting
An Essential Role For Caspase-1 In The Induction Of Murine Lupus and Its Associated Vascular Damage
J. Michelle Kahlenberg¹, Srilakshmi Yalavarthi², Wenpu Zhao², Jeffrey Hodgin³, Tamra J. Reed⁴, Noriko M. Tsuji⁵ and Mariana J. Kaplan⁶, ¹Internal Medicine, Division of Rheumatology, University of Michigan, Ann Arbor, MI, ²University of Michigan Rheumatology, Ann Arbor, MI, ³Department of Pathology, University of Michigan, Ann Arbor, MI, ⁴Internal Medicine, Rheumatology, University of Michigan, Ann Arbor, MI, ⁵3Biomedical Research Institute, National Institute of Advanced Industrial Science and Technology, Tsukuba, Japan, ⁶Systemic Autoimmunity Branch, National Institutes of Health/NIAMS, Bethesda, MD
Background/Purpose: Systemic Lupus Erythematosus (SLE) is a systemic autoimmune syndrome associated with organ damage and an elevated risk of cardiovascular disease (CVD) resulting from activation…
Abstract Number: 501 • 2013 ACR/ARHP Annual Meeting
A Randomized Placebo-Controlled Phase 2 Study To Evaluate Efficacy, Safety and Tolerability Of Two Secukinumab Loading Dose Regimens In Subjects With Active Rheumatoid Arthritis Despite Treatment With Methotrexate
Silvano Adami¹, André Beaulieu², Proton Rahman³, Bruno Seriolo⁴, Janet S. Lee⁵, Gerhard Krammer⁶, Brian Porter⁵, Anuradha Thulasiraman⁶ and Hanno B. Richards⁷, ¹Rheumatology Department, University of Verona, Verona, Italy, ²Faculty of Medicine, Laval University, Quebec, QC, Canada, ³Faculty of Medicine, Memorial University of Newfoundland, St. John's, NF, Canada, ⁴Research Laboratory and Academic Division of Clinical Rheumatology, Department of Internal Medicine, University of Genova, Genoa, Italy, ⁵Novartis Pharma AG, East Hanover, NJ, ⁶Novartis Pharma AG, Basel, Switzerland, ⁷Clinical Immunology / Dermatology, Novartis Pharma AG, Basel, Switzerland
A Randomized Placebo-Controlled Phase 2 Study to Evaluate Efficacy, Safety and Tolerability of Two Secukinumab Loading Dose Regimens in Subjects with Active Rheumatoid Arthritis Despite…
Abstract Number: 502 • 2013 ACR/ARHP Annual Meeting
Early Introduction Of Biologic Treatment Is An Important Predictor Of Sustained Favorable Outcome Including Clinical Remission In Early Arthritis But Not Of Sustained Favorable Outcome On Structure and Function Only: Results From The Espoir Cohort
Cécile Gaujoux-Viala¹, Laure Gossec², Maxime Dougados³, Francis Guillemin⁴ and Bruno Fautrel⁵, ¹EA 2415, Montpellier I University, Nîmes University Hospital, Rheumatology Department, Nîmes, France, ²Rheumatology, Paris 6 – Pierre et Marie Curie University; AP-HP, Rheumatology, Pitié-Salpêtrière Hospital, - GRC-UPMC 08 – EEMOIS, Paris, France, ³Rheumatology B Department, Paris-Descartes University, APHP, Cochin Hospital, Paris, France, ⁴CHU Nancy, Clinical Epidemiology and Evaluation, Université de Lorraine, Paris Descartes University, APEMAC, EA 4360, Nancy, France, ⁵Paris 6 – Pierre et Marie Curie University; AP-HP, Rheumatology, Pitié-Salpêtrière Hospital, - GRC-UPMC 08 – EEMOIS, Paris, France
Background/Purpose: The relevant elements to evaluate health states in RA should include remission, good functional ability and structural stability [1]. The concept of favorable outcome…
Abstract Number: 503 • 2013 ACR/ARHP Annual Meeting
Sjögren’s Syndrome In American Ethnic and Racial Minorities
Ann Igoe¹, Christopher J. Lessard^2,3, Juan-Manuel Anaya⁴, Astrid Rasmussen², Kiely Grundahl⁵, Biji T. Kurien^6,7,8, Jacen S Maier-Moore⁹, Lida Radfar¹⁰, John A. Ice², Glen D. Houston¹¹, David M. Lewis¹², Donald U. Stone¹³, Kimberly S. Hefner¹⁴, Kathy L. Sivils^2,3 and R. Hal Scofield^6,8,15, ¹Arthritis & Clinical Immunology, Oklahoma Medical Research Foundation, Oklahoma City, OK, ²Arthritis and Clinical Immunology Research Program, Oklahoma Medical Research Foundation, Oklahoma City, OK, ³Department of Pathology, University of Oklahoma Health Sciences Center, Oklahoma City, OK, ⁴Center for Autoimmune Diseases Research (CREA), Universidad del Rosario., Bogota, Colombia, ⁵Arthritis and Clinical Immunology Research Program, Oklahoma Medical Research Foundation, oklahoma CIty, OK, ⁶Oklahoma Medical Research Foundation, Oklahoma City, OK, ⁷U.S. Department of Veterans Affairs Medical Center, Oklahoma City, OK, ⁸College of Medicine, University of Oklahoma Health Sciences Center, Oklahoma City, OK, ⁹Medicine; Arthritis & Clinical Immunology, University of Oklahoma Health Sciences Center, Oklahoma Medical Research Foundation, Department of Veterans Affairs, Oklahoma City, OK 73104, Oklahoma City, OK, ¹⁰College of Dentristry, University of Oklahoma Health Sciences Center, Oklahoma City, OK, ¹¹Collage of Denistry, University of Oklahoma Health Sciences Center, Oklahoma City, OK, ¹²College of Dentistry, University of Oklahoma Health Sciences Center, Oklahoma City, OK, ¹³Department of Ophthalmology, Dean McGee Eye Institute, University of Oklahoma Health Sciences Center, Oklahoma City, OK, ¹⁴Hefner Eye Care and Optical Center, Oklahoma City, OK, ¹⁵US Department of Veterans Affairs Medical Center, Oklahoma City, OK
Background/Purpose: Examine the racial and ethnic make-up of a large cohort of Sjögren’s syndrome (SS) gathered in the USA compared to the make-up found among…
Abstract Number: 504 • 2013 ACR/ARHP Annual Meeting
Raynaud’s Phenomenon and African American Race Are Independently Associated With Non-Hodgkin’s Lymphoma In Sjogrens Syndrome Patients: Findings From a United States National Study
Bella Mehta¹, Neville Jadeja², Marjan Mujib³ and Petros V. Efthimiou⁴, ¹Internal Medicine, Westchester Medical Center at New York Medical College, valhalla, NY, ²Internal Medicine, Jacobi Medical Center, New York, NY, ³Internal Medicine, New York Medical College, Valhalla, NY, ⁴Medicine/Rheumatology, LM&MHC/Weill Cornell MC, New York, NY
Background/Purpose: , Higher incidence of lymphoma in sjogrens syndrome has been reported since more than 5 decades now. Non Hodgkin's Lymphoma (NHL) ranks as the…
Abstract Number: 505 • 2013 ACR/ARHP Annual Meeting
Damage Accrual In a Single Centre Cohort Of Patients With Primary Sjögren’s Syndrome Followed Up For Over 10 Years
Chiara Baldini¹, Francesco Ferro¹, Pasquale Pepe², Nicoletta Luciano¹, Francesca Sernissi¹, Carlotta Cacciatore¹, Daniela Martini¹, Antonio Tavoni³, Marta Mosca⁴ and Stefano Bombardieri¹, ¹University of Pisa, Rheumatology Unit, Pisa, Italy, ²Institute of Clinical Physiology, National Research Council, Pisa, Italy, ³University of Pisa, Immunoallergology Unit, Pisa, Italy, ⁴Rheumatology Unit, University of Pisa, Pisa, Italy
Background/Purpose: 1) To describe the progression and cumulative prevalence of damage accrued over the time in a single center cohort of patients with primary Sjögren’s…
Abstract Number: 506 • 2013 ACR/ARHP Annual Meeting
Hospitalization In Patients With Primary Sjögren’s Syndrome
Yemil Atisha-Fregoso¹, Yahaira Rivera² and Gabriela Hernandez-Molina², ¹Internal Medicine, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico, ²Immunology and Rheumatology, Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubirán, Mexico City, Mexico
Background/Purpose: There is scant information on the frequency, main causes and associated risk factors of hospitalization in patients with primary Sjögren syndrome (PSS).We aimed to…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].